D-Index & Metrics Best Publications

D-Index & Metrics

Discipline name D-index D-index (Discipline H-index) only includes papers and citation values for an examined discipline in contrast to General H-index which accounts for publications across all disciplines. Citations Publications World Ranking National Ranking
Immunology D-index 67 Citations 18,910 148 World Ranking 1227 National Ranking 649
Medicine D-index 81 Citations 29,020 265 World Ranking 9080 National Ranking 4928

Overview

What is she best known for?

The fields of study she is best known for:

  • Internal medicine
  • Disease
  • Gene

Joan T. Merrill mainly focuses on Internal medicine, Lupus erythematosus, Immunology, Placebo and Connective tissue disease. Her studies in Internal medicine integrate themes in fields like Gastroenterology and Surgery. Joan T. Merrill has researched Lupus erythematosus in several fields, including Systemic lupus erythematosus, Randomized controlled trial, Human leukocyte antigen and Cohort.

Her Immunology study combines topics in areas such as Genotype, Single-nucleotide polymorphism and Haplotype. Her research in Placebo intersects with topics in Belimumab and Adverse effect, Pharmacology. Her Connective tissue disease research incorporates elements of Systemic disease, Immunopathology and Quality of life.

Her most cited work include:

  • Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. (2280 citations)
  • Human polymorphism at microRNAs and microRNA target sites. (1284 citations)
  • Genome-wide association scan in women with systemic lupus erythematosus identifies susceptibility variants in ITGAM, PXK, KIAA1542 and other loci. (1069 citations)

What are the main themes of her work throughout her whole career to date?

Joan T. Merrill mainly investigates Internal medicine, Immunology, Systemic lupus erythematosus, Lupus erythematosus and Rheumatology. The various areas that Joan T. Merrill examines in her Internal medicine study include Gastroenterology and Placebo. She regularly ties together related areas like Disease in her Immunology studies.

Her Systemic lupus erythematosus study deals with Cohort intersecting with Cohort study. Her research investigates the connection between Lupus erythematosus and topics such as Connective tissue disease that intersect with issues in Immunopathology. Her Rheumatology research is multidisciplinary, relying on both Quality of life, Systemic lupus, Physical therapy, Pediatrics and INCEPTION COHORT.

She most often published in these fields:

  • Internal medicine (52.77%)
  • Immunology (48.69%)
  • Systemic lupus erythematosus (39.36%)

What were the highlights of her more recent work (between 2017-2021)?

  • Internal medicine (52.77%)
  • Systemic lupus erythematosus (39.36%)
  • Lupus erythematosus (25.66%)

In recent papers she was focusing on the following fields of study:

Her primary areas of study are Internal medicine, Systemic lupus erythematosus, Lupus erythematosus, Clinical trial and Placebo. In her research, Joan T. Merrill performs multidisciplinary study on Internal medicine and In patient. Joan T. Merrill interconnects Disease severity, Anti-nuclear antibody, Quality of life, Immune system and Abatacept in the investigation of issues within Systemic lupus erythematosus.

Her study in Lupus erythematosus is interdisciplinary in nature, drawing from both Young adult, Pregnancy, Physical therapy and Severity of illness. Her Placebo study also includes fields such as

  • Arthritis which connect with Rash and Gastroenterology,
  • Randomization which connect with Phases of clinical research. Her biological study spans a wide range of topics, including Antibody and Immunology.

Between 2017 and 2021, her most popular works were:

  • Emerging evidence of a COVID-19 thrombotic syndrome has treatment implications. (66 citations)
  • Phase III trial results with blisibimod, a selective inhibitor of B-cell activating factor, in subjects with systemic lupus erythematosus (SLE): results from a randomised, double-blind, placebo-controlled trial (43 citations)
  • Lupus community panel proposals for optimising clinical trials: 2018 (31 citations)

In her most recent research, the most cited papers focused on:

  • Internal medicine
  • Disease
  • Cancer

Internal medicine, Lupus erythematosus, Systemic lupus erythematosus, Young adult and Clinical trial are her primary areas of study. Her Internal medicine study frequently draws connections to other fields, such as Placebo. Her studies deal with areas such as Odds ratio, Pregnancy, Predictive value of tests and Severity of illness as well as Lupus erythematosus.

In her research, Complex disease, Physical therapy and Systemic therapy is intimately related to Disease activity, which falls under the overarching field of Systemic lupus erythematosus. Her work deals with themes such as Polypharmacy, Intensive care medicine and Adverse effect, which intersect with Clinical trial. Her Transcriptome research includes themes of Plasma cell and Immunology.

This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.

Best Publications

Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus.

Michelle Petri;Ana Maria Orbai;Graciela S. Alarcõn;Caroline Gordon.
Arthritis & Rheumatism (2012)

3514 Citations

Human polymorphism at microRNAs and microRNA target sites.

Liuqing Yang;Chunru Lin;Chunyu Jin;Joy C. Yang.
Frontiers in Genetics (2013)

2058 Citations

Efficacy and Safety of Rituximab in Moderately-to-Severely Active Systemic Lupus Erythematosus: The Randomized, Double-Blind, Phase II/III Systemic Lupus Erythematosus Evaluation of Rituximab Trial

Joan T. Merrill;C. Michael Neuwelt;Daniel J. Wallace;Joseph C. Shanahan.
Arthritis & Rheumatism (2010)

1359 Citations

American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis

Bevra H. Hahn;Maureen A. McMahon;Alan Wilkinson;W. Dean Wallace.
Arthritis Care and Research (2012)

1287 Citations

Genome-wide association scan in women with systemic lupus erythematosus identifies susceptibility variants in ITGAM, PXK, KIAA1542 and other loci.

John B. Harley;John B. Harley;John B. Harley;Marta E. Alarcón-Riquelme;Lindsey A. Criswell;Chaim O. Jacob.
Nature Genetics (2008)

1284 Citations

A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus

Richard Furie;Michelle Petri;Omid Zamani;Ricard Cervera.
Arthritis & Rheumatism (2011)

1212 Citations

Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis

Ellen M. Ginzler;Mary Anne Dooley;Cynthia Aranow;Mimi Y. Kim.
The New England Journal of Medicine (2005)

1204 Citations

The effect of combined estrogen and progesterone hormone replacement therapy on disease activity in systemic lupus erythematosus: A randomized trial

Jill P. Buyon;Michelle A. Petri;Mimi Y. Kim;Kenneth C. Kalunian.
Annals of Internal Medicine (2005)

588 Citations

Anifrolumab, an Anti–Interferon-α Receptor Monoclonal Antibody, in Moderate-to-Severe Systemic Lupus Erythematosus

Richard Furie;Munther Khamashta;Joan T. Merrill;Victoria P. Werth.
Arthritis & Rheumatism (2017)

544 Citations

A Phase II, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of Belimumab in Patients With Active Systemic Lupus Erythematosus

Daniel J. Wallace;William Stohl;Richard A. Furie;Jeffrey R. Lisse.
Arthritis Care and Research (2009)

538 Citations

If you think any of the details on this page are incorrect, let us know.

Contact us

Best Scientists Citing Joan T. Merrill

Michelle Petri

Michelle Petri

Johns Hopkins University School of Medicine

Publications: 162

John B. Harley

John B. Harley

Cincinnati Children's Hospital Medical Center

Publications: 142

Marta E. Alarcón-Riquelme

Marta E. Alarcón-Riquelme

University of Granada

Publications: 129

Judith A. James

Judith A. James

Oklahoma Medical Research Foundation

Publications: 127

David A. Isenberg

David A. Isenberg

University College London

Publications: 121

Yehuda Shoenfeld

Yehuda Shoenfeld

Sheba Medical Center

Publications: 106

Andrea Doria

Andrea Doria

University of Padua

Publications: 94

Ole A. Andreassen

Ole A. Andreassen

Oslo University Hospital

Publications: 92

Graciela S. Alarcón

Graciela S. Alarcón

University of Alabama at Birmingham

Publications: 90

Timothy J. Vyse

Timothy J. Vyse

King's College London

Publications: 87

Ricard Cervera

Ricard Cervera

University of Barcelona

Publications: 82

Stephan Ripke

Stephan Ripke

Massachusetts General Hospital

Publications: 81

Carl D. Langefeld

Carl D. Langefeld

Wake Forest University

Publications: 79

Daniel J. Wallace

Daniel J. Wallace

University of California, Los Angeles

Publications: 79

Iva Gunnarsson

Iva Gunnarsson

Karolinska University Hospital

Publications: 77

Murray B. Urowitz

Murray B. Urowitz

Toronto Western Hospital

Publications: 77

Trending Scientists

Kai Yu

Kai Yu

Horizon Robotics Inc.

Ben Upcroft

Ben Upcroft

Queensland University of Technology

Georges L. Chahine

Georges L. Chahine

Dynaflow, Inc.

Nicola Pugno

Nicola Pugno

University of Trento

Gregory E. Hilmas

Gregory E. Hilmas

Missouri University of Science and Technology

Miguel Verdú

Miguel Verdú

Spanish National Research Council

Seiichiro Hasezawa

Seiichiro Hasezawa

University of Tokyo

Eero Vuorio

Eero Vuorio

University of Turku

Kadarkarai Murugan

Kadarkarai Murugan

Bharathiar University

Dennis K. Bird

Dennis K. Bird

Stanford University

Ina Bornkessel-Schlesewsky

Ina Bornkessel-Schlesewsky

University of South Australia

Roy G. Smith

Roy G. Smith

Scripps Research Institute

Louis Gooren

Louis Gooren

VU University Medical Center

Rolv T. Lie

Rolv T. Lie

University of Bergen

Carl A. Castro

Carl A. Castro

University of Southern California

Something went wrong. Please try again later.